Clustering of cardiovascular risk factors and metabolic syndrome prevalence in subjects with resistant hypertension;Agregación de factores de riesgo cardiovascular y de prevalencia de síndrome metabólico en personas con hipertensión arterial resistente

Medicina Clinica

Volumn 127, Issue 7, 2006, Pages 241-245

  Hernández Del Rey, Raquel ^a,b,c   Armario, Pedro ^a,b   Martín Baranera, Montserrat ^a,b   Castellanos, Pere ^a,b  

^a HOSPITAL GENERAL DE CATALUNYA   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c Hospital General de l'Hospitalet   (Spain)

Author keywords

Cardiovascular risk factors; Metabolic syndrome; Resistant hypertension

Indexed keywords

ANTIHYPERTENSIVE AGENT; DIURETIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; AMBULATORY CARE; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETES MELLITUS; DOPPLER ECHOCARDIOGRAPHY; ECHOCARDIOGRAPHY; FEMALE; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PATIENT COMPLIANCE; PREVALENCE; SITTING;

EID: 33748431240     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13091263     Document Type: Article

References (38)

1. Banegas JR, Rodriguez-Artalejo F, De la Cruz Troca JJ, Guallar-Castillon P, Rey Calera J. Blood pressure in Spain. Distribution, awareness, control, and benefits of reduction in average pressure. Hypertension. 1998;32:998-1002.
2. Coca A. Evolución del control de la hipertensión arterial en atención primaria en España. Resultados del estudio Controlpres 2003. Hipertension. 2005;22:5-14.
3. Banegas JR, Segura J, Ruilope LM, Luque M, Garća-Robles R, Campo C, et al. Blood pressure control and physician management of hypertensin in hospital hypertension units in Spain. Hypertension. 2004;43:1338-44.
4. Yakovlevitch M, Black HR. Resistant hypertension in a tertiery care clinic. Arch Intern Med. 1991;151:1786-92.
5. Hernàndez del Rey R, Armario P, Mart́n-Baranera M, Sánchez P, Cárdenas G, Pardell H. Target-organ damage and cardiovascular risk profile in resistant hypertension. Influence of the white-coat effect. Blood Press Monit. 1998;3:331-7.
6. Garg JP, Elliot WJ, Folker A, Izhar M, Black HR, for the RUSH University Hypertension Service. Resistant hypertension revisited: a comparison of two university-based cohorts. Am J Hypertens. 2005;18:619-26.
7. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure: the sixth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997;157:2413-46.
8. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure: the seven Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. JAMA. 2003;289:2560-72.
9. Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21:1011-53.
10. Isaksson H, Danielsson M, Rosenhamer G, Konarski-Svenson JC, Östergren J. Characteristics of patients resistant to antihypertensive drug therapy. J Inter Med. 1991;229:421-6.
11. Toner JM, Close CF, Ramsay LE. Factors related to treatment resistance in hypertension. Quartely J Med. 1990;77:1195-204.
12. Isaksson H, Cederholm T, Jansson E, Nygren A, Östergren J. Therapy-resistan hypertension associated with central obesity, insulin resistance, and large muscle fibre area. Blood Press. 1993;2:46-52.
13. Martell N, Rodríguez-Cerillo M, Grobbee DE, López-Eady MD, Fernández-Pinilla C, Avila M, et al. High prevalence of secondary hypertension and insulin resistance in patients with refractory hypertension Blood Press. 2003;12:149-54.
14. Gutiérez-Fisac, Regido E, Banegas JR, Rodríguez-Artelejo F. Prevalencia de obesidad en la poblacion adulta española: 14 anos de incremento continuado. Med Clin (Barc). 2005;124:44-5.
15. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97.
16. World Health Organisation. Report of a WHO consultation: definition of metabolic syndrome. En: Department of Noncommunicable Disease Surveillance World Health Organization, editor. Definition, diagnosis and classification of diabetes mellitus and its complications. Geneva: WHO; 1999.
17. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomiletho J, et al. The metabolic syndrome and total cardiovascular disease mortality in middle-ages men. JAMA. 2002;288:2709-16.
18. Hu G, Qiao Q, Toumilehto J, Balkau, Boro-Johnsen K. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med. 2004;164:1066-76.
19. Schillaci G, Pirro M, Vaudo G, Gemelli F, Marchesi S, Porcellati C, et al. Prognostic value of the metabolic syndrome in essential hypertension. J Am Coll Cardiol. 2004;43:1817-22.
20. Modan M, Almog S, Fuchs Z, Chetrit A, Lusky A, Halkin H. Obesity, glucose intolerance, hyperin-sulinemia, and response to anthihypertensive drugs. Hypertension. 1991;17:565-73.
21. Isaksson H, Östergren J. Prognosis in therapy-resistant hypertension. J Intern Med. 1994;236:643-9.
22. Redon J, Campos C, Narciso ML, Rodicio JL, Pascual JM, Ruilope LM. Prognostic value of ambulatory blood pressure monitoring in refractory hypertension. A prospective study. Hypertension. 1998;31:712-8.
23. Benetos A, Thomas F, Bean K, Gautier S, Smulyan H, Guize L. Prognostic value of systolic and diastolic blood pressure in treated hypertensive men. Arch Intern Med. 2002;162:577-81.
24. Verdecchia P, Reboldi G, Porcellati C, Scillaci G, Pee S, Bentivoglio M, et al. Risk of cardiovascular disease in relation to achieved office and ambulatory blood pressure control in treated hypertensive subjects. J Am Coll Cardiol. 2002;39:878-85.
25. Cuspidi C, Macca G, Sampieri L, Michev I, Salerno M, Fusi V, et al. High prevalence of cardiac and extracardiac target organ damage in refractory hypertension. J Hypertens. 2001;19:2063-70.
26. 1999 World Health Organization-International Society of Hypertension. Guidelines for the management of hypertension. Guidelines Subcommittee. J Hypertens. 1999;17:151-83.
27. Armario P, Hernández del Rey R, Sánchez P, Martin-Baranera M, Torres G, Julia J, et al. Determinants of left ventricular mass in untread mildly hypertensive subjects. Hospitalet Study in mild hypertension. Am J Hypertens. 1999;12:1084-90.
28. Koren MJ, Devereux RB, Casle PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med. 1991;114:345-52.
29. EUROSPIDE I and II Group. Clinical reality of coronary prevention guidelines: a comparasion of EUROSPIDE I and II in nine countries. Lancet. 2001;357:995-1001.
30. Savage DB, Petersen KF, Shulman GI. Mechanisms of insulin resistance in humans and possible links with inflammation. Hypertension. 2005;45:828-33.
31. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities. The role of insulinresistance and the sympathoadrenal system. N Engl J Med. 1996;334:374-81.
32. Landsberg L. Insulin-mediated sympathetic stimulation: role in the pathogenesis of obesity-related hypertension (or, how insulin affects blood pressure, and why). J Hypertens. 2001;19:523-8.
33. Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C, for conference participants. Definition of metabolic syndrome. Report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association Conference on Scientific Issues Related to management. Circulation. 2004;109:433-8.
34. Alvarez Cosmea A, López Fernández V, Suárez García S, Arias García T, Prieto Díaz MA, Díaz González L Diferencias en la prevalencia del sindrome metabolico segun las definiciones del ATP III y la OMS. Med Clin (Barc). 2005;124:368-70.
35. Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Hymsfield SB. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutition Examination Survey, 1988-1994. Arch Intern Med. 2003;163:427-36.
36. Thomas F, Rudnichi A, Bacri AM, Bean K, Guize L, Benetos A. Cardiovascular mortality in hypertensive men according to presence of associated risk factors. Hypertension. 2001;37:1256-61.
37. Amar J, Chamontin B, Genes N, Cantet C, Salvador M, Cambou JP. Why is hypertension so frecuenty uncontrolled in secondary prevention? J Hypertens. 2003;21:1199-205.
38. Logan AG, Perlikowski SM, Mente A, Tisler A, Tkacova R, Niroumand M, et al. High prevalence of unrecognized sleep apnea in drug-resistant hypertension. J Hypertens. 2001;19:2271-7.